ADTX
Aditxt Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
196,180
P/E Ratio
—
EPS
$-9230.64
Beta
1.40
52W High
$2495.04
52W Low
$0.19
50-Day MA
$1.75
200-Day MA
$312.73
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
0.35
PEG Ratio
—
About Aditxt Inc.
Aditxt Inc. is an innovative biotechnology firm dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. The company focuses on enhancing immune responses to effectively address chronic diseases and allergies, ultimately improving patient outcomes. With a robust pipeline of therapeutic candidates supported by extensive research and strategic collaborations, Aditxt is poised to become a leader in the burgeoning field of immune-based therapies. By prioritizing scientific advancements and patient-centered solutions, Aditxt aims to significantly impact the future of immunology and the broader healthcare landscape.
Fundamentals
| Revenue (TTM) | 3,195 |
| Gross Profit (TTM) | 268 |
| EBITDA | $-19.30M |
| Operating Margin | -1098726.00% |
| Return on Equity | -699.00% |
| Return on Assets | -50.30% |
| Revenue/Share (TTM) | $0.09 |
| Book Value | $13.63 |
| Price-to-Book | 0.04 |
| Price-to-Sales (TTM) | 61.40 |
| EV/Revenue | 1.294 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -86.60% |
| Shares Outstanding | 904,470 |
| Float | 884,920 |
| % Insiders | 2.16% |
| % Institutions | 3.88% |
Data last updated: 4/30/2026